Novavax to Raise $200 Million from Private Placement with RA Capital
“We are extremely pleased to receive this tremendous support from
“The global vaccine effort is searching for candidates that are capable of both generating the highest neutralizing antibody titers and large-scale production. We are excited to increase our investment in
The preferred stock is not entitled to cumulative dividends, and is not entitled to vote on matters submitted to the holders of
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security. The shares of preferred stock referenced herein have not been registered under the Securities Act of 1933, as amended (Securities Act), or applicable state securities laws and may not be offered or sold in
Statements herein relating to the future of
Source: Novavax, Inc.